SCHEMBL7850756

SCHEMBL7850756

COC(Cc1ccc(OCC=C2c3cnccc3-c3cccnc32)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 18/20 0.54
PPARA Q07869 16/20 0.54
PPARD Q03181 12/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7850753 1.00 PPARG (0.54) PPARGPPARAPPARD
SCHEMBL7851931 0.91 PPARG (0.50) PPARGPPARAPPARD
SCHEMBL7852809 0.91 PPARA (0.68) PPARGPPARAPPARD
SCHEMBL7851926 0.91 PPARG (0.50) PPARGPPARAPPARD
SCHEMBL7852808 0.91 PPARA (0.68) PPARGPPARAPPARD
SCHEMBL7853266 0.90 PPARG (0.59) PPARGPPARAPPARD
SCHEMBL7843290 0.90 PPARG (0.59) PPARGPPARAPPARD
SCHEMBL7843860 0.90 PPARG (0.49) PPARGPPARAPPARD
SCHEMBL7843858 0.90 PPARG (0.49) PPARGPPARAPPARD
SCHEMBL7843823 0.86 PPARA (0.59) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US claimed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US disclosed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed